Suscribirse

Integrating Pharmacogenomics into Clinical Practice: Promise vs Reality - 25/09/16

Doi : 10.1016/j.amjmed.2016.04.009 
Jennifer L. St. Sauver, PhD a, , Suzette J. Bielinski, PhD a, Janet E. Olson, PhD a, Elizabeth J. Bell, PhD a, Michaela E. Mc Gree, BS b, Debra J. Jacobson, MS b, Jennifer B. McCormick, PhD c, Pedro J. Caraballo, MD d, Paul Y. Takahashi, MD e, Veronique L. Roger, MD f, Carolyn R. Rohrer Vitek, MS g
a Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minn 
b Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minn 
c Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, Minn 
d Department of General Internal Medicine, Mayo Clinic, Rochester, Minn 
e Department of Primary Care Internal Medicine, Mayo Clinic, Rochester, Minn 
f Division of Cardiovascular Diseases, Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minn 
g Center for Individualized Medicine, Mayo Clinic, Rochester, Minn 

Requests for reprints should be addressed to Jennifer L. St. Sauver, PhD, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.Mayo Clinic200 First Street SWRochesterMN55905

Abstract

Background

Limited information is available regarding primary care clinicians' response to pharmacogenomic clinical decision support (PGx-CDS) alerts integrated in the electronic health record.

Methods

In February 2015, 159 clinicians in the Mayo Clinic primary care practice were sent e-mail surveys to understand their perspectives on the implementation and use of pharmacogenomic testing in their clinical practice. Surveys assessed how the clinicians felt about pharmacogenomics and whether they thought electronic PGx-CDS alerts were useful. Information was abstracted on the number of CDS alerts the clinicians received between October 2013 and the date their survey was returned. CDS alerts were grouped into 2 categories: the alert recommended caution using the prescription, or the alert recommended an alternate prescription. Finally, data were abstracted regarding whether the clinician changed their prescription in response to the alert recommendation.

Results

The survey response rate was 57% (n = 90). Overall, 52% of the clinicians did not expect to use or did not know whether they would use pharmacogenomic information in their future prescribing practices. Additionally, 53% of the clinicians felt that the alerts were confusing, irritating, frustrating, or that it was difficult to find additional information. Finally, only 30% of the clinicians that received a CDS alert changed their prescription to an alternative medication.

Conclusions

Our results suggest a lack of clinician comfort with integration of pharmacogenomic data into primary care. Further efforts to refine PGx-CDS alerts to make them as useful and user-friendly as possible are needed to improve clinician satisfaction with these new tools.

El texto completo de este artículo está disponible en PDF.

Keywords : Clinical practice patterns, Genomics, Pharmacogenetics, Practice patterns


Esquema


 Funding: This research was funded by the Mayo Clinic Center for Individualized Medicine and the Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery.
 Conflict of Interest: The authors have no conflicts of interest to report.
 Authorship: All authors had access to the data and a role in writing the manuscript.


© 2016  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 129 - N° 10

P. 1093 - octobre 2016 Regresar al número
Artículo precedente Artículo precedente
  • Hypothyroid Symptoms Fail to Predict Thyroid Insufficiency in Old People: A Population-Based Case-Control Study
  • Allan Carlé, Inge Bülow Pedersen, Nils Knudsen, Hans Perrild, Lars Ovesen, Stig Andersen, Peter Laurberg
| Artículo siguiente Artículo siguiente
  • Mitral Valve Prolapse, Psychoemotional Status, and Quality of Life: Prospective Investigation in the Current Era
  • Tali Bayer-Topilsky, Rakesh M. Suri, Yan Topilsky, Yariv N. Marmor, Max R. Trenerry, Ryan M. Antiel, Douglas W. Mahoney, Hartzell V. Schaff, Maurice Enriquez-Sarano

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.